Immuneering Statistics Share Statistics Immuneering has 36.3M
shares outstanding. The number of shares has increased by 21.35%
in one year.
Shares Outstanding 36.3M Shares Change (YoY) 21.35% Shares Change (QoQ) 0.27% Owned by Institutions (%) 12.66% Shares Floating 26.05M Failed to Deliver (FTD) Shares 567 FTD / Avg. Volume 0.04%
Short Selling Information The latest short interest is 1.58M, so 4.35% of the outstanding
shares have been sold short.
Short Interest 1.58M Short % of Shares Out 4.35% Short % of Float 5.69% Short Ratio (days to cover) 4.58
Valuation Ratios The PE ratio is -1.08 and the forward
PE ratio is -3.35.
Immuneering's PEG ratio is
-0.13.
PE Ratio -1.08 Forward PE -3.35 PS Ratio 0 Forward PS 9.4 PB Ratio 1.59 P/FCF Ratio -1.2 PEG Ratio -0.13
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Immuneering.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.28,
with a Debt / Equity ratio of 0.1.
Current Ratio 5.28 Quick Ratio 5.28 Debt / Equity 0.1 Debt / EBITDA -0.07 Debt / FCF -0.08 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.13M Employee Count 54 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 366.95% in the
last 52 weeks. The beta is 0.43, so Immuneering's
price volatility has been higher than the market average.
Beta 0.43 52-Week Price Change 366.95% 50-Day Moving Average 4.11 200-Day Moving Average 2.37 Relative Strength Index (RSI) 61.94 Average Volume (20 Days) 1,476,846
Income Statement
Revenue n/a Gross Profit -713.45K Operating Income -64.07M Net Income -61.04M EBITDA -63.69M EBIT -64.07M Earnings Per Share (EPS) -2.04
Full Income Statement Balance Sheet The company has 36.15M in cash and 4.16M in
debt, giving a net cash position of 31.98M.
Cash & Cash Equivalents 36.15M Total Debt 4.16M Net Cash 31.98M Retained Earnings -224.29M Total Assets 40.06M Working Capital 20.24M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -55M
and capital expenditures -84.88K, giving a free cash flow of -55.08M.
Operating Cash Flow -55M Capital Expenditures -84.88K Free Cash Flow -55.08M FCF Per Share -1.84
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
